Molecular target
VEGF / VEGFR Angiogenesis Signaling
Also: VEGFR, Angiogenesis · id VEGF_SIGNALING
Vascular endothelial growth factor signaling that drives tumor angiogenesis; targeted by multi-kinase anti-angiogenic drugs (sunitinib, sorafenib, pazopanib, lenvatinib). Several botanicals (green tea, curcumin, resveratrol, soy isoflavones) have been investigated for anti-angiogenic activity in laboratory studies.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on VEGF / VEGFR Angiogenesis Signaling
These medications have VEGF / VEGFR Angiogenesis Signaling among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on VEGF / VEGFR Angiogenesis Signaling
Each plant below contains a named compound documented to act on VEGF / VEGFR Angiogenesis Signaling. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- CurcuminPolyphenol (curcuminoid)
Beyond its anti-inflammatory NF-kB/COX/LOX activity, curcumin has been investigated in preclinical cancer models for EGFR-pathway and PI3K–Akt–mTOR signaling inhibition and for anti-angiogenic (VEGF) effects. Research only — not a treatment claim.
- Trans-resveratrolStilbenoid polyphenol
Alongside SIRT1/NF-kB activity, resveratrol has been studied for PI3K–Akt–mTOR pathway modulation and anti-angiogenic (VEGF) effects in preclinical models. Research only — not a treatment claim.